Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clopidogrel: background information and use in clinical practice].

Birgitte Klindt Ziegler1, Lars Hvilsted Rasmussen, Steen Dalby Kristensen

  • 1Arhus Universitetshospital, Arhus Amtssygehus, Klinisk Farmakologisk Afdeling, Aalborg Sygehus, Kardiologisk Afdeling.

Ugeskrift for Laeger
|May 30, 2003
PubMed
Summary

Clopidogrel, an antiplatelet medication, effectively prevents platelet aggregation by blocking ADP receptors. This review covers its pharmacology and clinical use in preventing cardiovascular events like heart attack and stroke.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Point-of-Care System for the Quantification of Small-Molecule Drugs in Blood.

ACS sensors·2026
Same author

Cyclooxygenase-1-Inhibition with Aspirin in Patients with Chronic Coronary Syndrome.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Effects of Acute Exercise and 12-Week High-Intensity Interval Training on Inflammatory Biomarkers in Stable Coronary Artery Disease: A Randomized Controlled Trial.

Journal of the American Heart Association·2026
Same author

MicroRNA dynamics and their link to platelet function following acute ST-segment elevation myocardial infarction.

Thrombosis research·2025
Same author

Everolimus-eluting versus biolimus-eluting stents with biodegradable polymers in unselected patients undergoing percutaneous coronary intervention: five-year results of the randomised, non-inferiority SORT OUT VIII trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2025
Same author

Biolimus-Eluting Biomatrix Stent vs a Dual-Therapy Sirolimus-Eluting Stent in PCI: The SORT OUT XI Randomized Trial.

Journal of the American College of Cardiology·2025

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Atherosclerosis leads to acute cardiovascular events such as myocardial infarction and ischemic stroke, major causes of mortality.
  • Platelet activation, adhesion, and aggregation are critical steps following atherosclerotic plaque rupture.
  • Antithrombotic therapy is vital for reducing mortality and morbidity in cardiovascular disease prevention.

Purpose of the Study:

  • To review the pharmacological mechanisms of Clopidogrel, a thienopyridine.
  • To examine the clinical evidence supporting Clopidogrel's efficacy in monotherapy and combination therapy with aspirin.
  • To provide comprehensive documentation on Clopidogrel's role in preventing atherothrombotic events.

Main Methods:

  • Review of pharmacological data on Clopidogrel's mechanism of action.

Related Experiment Videos

  • Analysis of clinical trial data and observational studies on Clopidogrel's effectiveness.
  • Evaluation of studies assessing Clopidogrel in monotherapy versus combination therapy with acetylsalicylic acid.

    • Main Results:

    • Clopidogrel irreversibly inhibits platelet aggregation by blocking P2Y12 adenosine diphosphate (ADP) receptors.
    • Clinical studies demonstrate significant reductions in adverse cardiovascular events with Clopidogrel treatment.
    • Combination therapy with acetylsalicylic acid may offer additional benefits in specific patient populations.

    Conclusions:

    • Clopidogrel is a key antiplatelet agent for managing and preventing atherothrombotic events.
    • Its specific mechanism targeting ADP receptors provides effective inhibition of platelet activation.
    • Evidence supports the use of Clopidogrel, alone or with aspirin, in primary and secondary cardiovascular prevention.